Neoadjuvant trastuzumab promising in breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1484, 2005-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant trastuzumab promising but costly for breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 500, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer

By  

Inpharma, Vol. 1, Iss. 1485, 2005-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Neoadjuvant docetaxel, vinorelbine and trastuzumab prior to surgery and adjuvant therapy is active in patients with HER-2 breast cancer

By  

Inpharma, Vol. 1, Iss. 1579, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

By Murthy Rashmi K.   Varma Ankur   Mishra Priyankana   Hess Kenneth R.   Young Elliana   Murray James L.   Koenig Kimberly H.   Moulder Stacy L.   Melhem-Bertrandt Amal   Giordano Sharon H.   Booser Daniel   Valero Vicente   Hortobagyi Gabriel N.   Esteva Francisco J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

Blackwell Publishing

Access to resources Recommend Favorite

In defence of trastuzumab for early breast cancer

By  

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite